Merus to Present at the Jefferies 2017 Global Healthcare Conference
(Thomson Reuters ONE) -
UTRECHT, The Netherlands, June 1, 2017 - Merus N.V. (Nasdaq: MRUS), a clinical-
stage immuno-oncology company developing innovative bispecific antibody
therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive
Officer, will present a company overview at the Jefferies 2017 Global Healthcare
Conference on Thursday, June 8, 2017 at 3:00 p.m. ET.
A live webcast of the presentation will be available on the Investors page of
the Company's website, http://www.merus.nl. An archived presentation will be
available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
share several features of conventional monoclonal antibodies, such as long half-
life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-
128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential
treatment for HER2-expressing solid tumors. Merus' second bispecific antibody
candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients
with acute myeloid leukemia. The Company also has a pipeline of proprietary
bispecific antibody candidates in preclinical development, including MCLA-158,
which is designed to bind to cancer stem cells and is being developed as a
potential treatment for colorectal cancer and other solid tumors, as well as
Biclonics® designed to bind to various combinations of immunomodulatory
molecules, including PD-1 and PD-L1.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza(at)argotpartners.com
Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly(at)argotpartners.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.06.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 545825
Anzahl Zeichen: 2465
contact information:
Town:
Utrecht
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 106 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merus to Present at the Jefferies 2017 Global Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Merus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
